-
1.发明授权Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments 有权与趋化因子受体CXCR3结合并用于慢性伤口和血管发生抑制治疗的趋化因子衍生肽公开(公告)号：US08734775B2
公开(公告)日：2014-05-27
申请号：US13219375
申请日：2011-08-26
IPC分类号： A61K38/19 , A61K45/00 , C07K14/435
CPC分类号： A61K38/195 , A61K47/551 , C07K14/522
摘要： Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
摘要翻译： 公开了具有针对受体CXCR3的活性的肽，其表现出在预防新血管形成中的活性和介导新形成的血管解离和在伤口愈合后期分解伤口的活性。 衍生自α-螺旋部分IP-10（CXCL10）或来自IP-9（CXCL11）的优选肽是无毒的且小于天然存在的肽，使得它们可用于治疗由不想要的血管发生标记的疾病或疾病状态， 包括肿瘤发生疾病如癌症，以及慢性伤口愈合。
-
2.发明申请CHEMOKINE DERIVED PEPTIDES AND USES FOR CHRONIC WOUND AND ANGIOGENESIS INHIBITION TREATMENTS 有权化学发光肽和用于慢性创伤和血管生成抑制治疗的用途公开(公告)号：US20130053319A1
公开(公告)日：2013-02-28
申请号：US13219375
申请日：2011-08-26
CPC分类号： A61K38/195 , A61K47/551 , C07K14/522
摘要： Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.
摘要翻译： 公开了具有针对受体CXCR3的活性的肽，其表现出在预防新血管形成中的活性和介导新形成的血管解离和在伤口愈合后期分解伤口的活性。 衍生自α-螺旋部分IP-10（CXCL10）或来自IP-9（CXCL11）的优选肽是无毒的且小于天然存在的肽，使得它们可用于治疗由不想要的血管发生标记的疾病或疾病状态， 包括肿瘤发生疾病如癌症，以及慢性伤口愈合。
-
公开(公告)号：US20140178451A1
公开(公告)日：2014-06-26
申请号：US14240132
申请日：2012-08-23
CPC分类号： A61K38/195 , A61K9/0048 , A61K38/217
摘要： The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof.
摘要翻译： 本公开内容描述了通过施用CXCR3的活化剂来治疗眼睛的血管生成疾病如黄斑变性，青光眼治疗后的再狭窄或糖尿病性视网膜病变的方法。 在一些实施方案中，CXCR3的活化剂是IP-10或其片段或变体，例如包含或由IP-10的C-末端α-螺旋组成的片段。 在其它实施方案中，CXCR3的活化剂是PF4或其片段或变体。
-
公开(公告)号：US09180167B2
公开(公告)日：2015-11-10
申请号：US14240132
申请日：2012-08-23
CPC分类号： A61K38/195 , A61K9/0048 , A61K38/217
摘要： The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3(CXCR3). In some embodiments, the activator of CXCR3 is interferon-γ-inducible 10 kDa protein (IP-10), or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
摘要翻译： 本公开内容描述了通过施用C-X-C趋化因子受体3（CXCR3）的活化剂来治疗眼睛的血管生成疾病如黄斑变性，青光眼治疗后的再狭窄或糖尿病性视网膜病变的方法。 在一些实施方案中，CXCR3的活化剂是干扰素-γ诱导型10kDa蛋白（IP-10）或其片段或变体，例如包含IP-10的C-末端α-螺旋或由其构成的片段。 在其它实施方案中，CXCR3的活化剂是血小板因子4（PF4）或其片段或变体。
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
